Molecular dynamics reveals how EED inhibitors bind in dual modes, implying insights into onco-targeting strategies.
The EED subunit of the Polycomb Repressive Complex 2 (PRC2) drives oncogenesis through histone methylation, and pharmacological EED inhibition effectively suppresses tumorigenic pathways. By combining molecular dynamics (MD), steered MD...
No takes yet. Share an insight, caveat, or question.
朱 et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: